North America Organoids Market Forecast to 2030 - Regional Analysis - by Organ Type (Intestine, Liver, Stomach, Pancreas, Lung, Brain, Kidney, and Others), Application (Development of Biology Disease, Pathology of infectious Disease, Regenerative Medicines, Drug Discovery and Personalized Medicine, Drug Toxicity and Efficacy Testing, and Others), Source (Pluripotent Stem Cell and Organ Specific Adult Stem Cell), and Type (Instruments, Consumables, and Services)
The North America organoid market is expected to grow from US$ 1,125.01 million in 2022 to US$ 5,359.72 million by 2030. It is estimated to grow at a CAGR of 21.5% from 2022 to 2030.
Growing Adoption of Personalized Drugs Fuel North America Organoids Market
Personalized medicine, also known as precision medicine, is a medical model that practices procedures or drugs tailored to the individual patient based on the projected response or risk of disease. According to a study published by Personalized Medicine Coalition (PMC), personalized medicines accounted for only 5% of the new FDA-approved molecular entities in 2005, whereas they accounted for more than 25% in 2016. Additionally, 42% of all compounds and 73% of oncology compounds in the pipeline have the potential to be personalized medicines. Moreover, biopharmaceutical companies nearly doubled their R&D investment in personalized drugs over the past five years, which is likely to increase by 33% in the next five years. Biopharmaceutical researchers also predict a 69% increase in the development of personalized medicines over the coming five years. According to the latest report by the PMC (published in 2021), in the US, the number of personalized medicines in the market has risen from 132 in 2016 to 286 in 2020. The data was shared by tracking the numbers of personalized medicine since 2008 by the PMC.
The implementation of organoids to create personalized drug therapies provides exciting opportunities for improving patient care. In addition, pharmacists play an essential role in increasing the demand for personalized medicines as they proactively educate and create awareness about precision medicine. Recent research has highlighted that more than 50% of consumers are interested in purchasing customized products or services. This demand has persuaded pharmaceutical research to develop more tailored treatments to make medicines safer and more effective.
Personalized cancer medicine is an approach to tailoring effective therapeutic strategies for each patient according to a tumor’s genomic characterization. There is an increasing demand for research in personalized tumor modeling to confirm the functional aspects of genomic drug response predictions in the preclinical setting. Numerous studies have highlighted the application of tumor organoids in personalized cancer medicine in terms of gene–drug association treatment, identification of new therapies, and prediction of patient outcomes.
Personalized cancer therapy applies specific treatments to each patient. Using personalized tumor models with similar characteristics to the original tumors may result in accurate predictions of drug responses in patients. Tumor organoid models have several advantages, such as conserving the molecular and cellular composition of the original tumor over pre-existing models. These advantages highlight the tremendous potential of tumor organoids in personalized cancer therapy, particularly in preclinical drug screening and predicting patient responses to selected treatment regimens.
North America Organoids Market Overview
The North America organoids market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest share of the North America organoids market. Rising number of patients suffering from chronic conditions and viral diseases, increasing activities in research and development, commercialization of organoid models, and breakthroughs in stem cell research are the key factors propelling the market for organoids. Also, the growing funding and grants for organoid development are favoring market expansion.
North America Organoid Market Revenue and Forecast to 2030 (US$ Million)
North America Organoids Market Segmentation
The North America organoid market is segmented into organ type, application, source, type, and country.
Based on organ type, the North America organoid market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held the largest share of the North America organoid market in 2022.
Based on application, the North America organoid market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held the largest share of the North America organoid market in 2022.
Based on source, the North America organoid market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held a larger share of the North America organoid market in 2022.
Based on type, the North America organoid market is segmented into instruments, consumables, and services. The consumables segment held the largest share of the North America organoid market in 2022.
Based on country, the North America organoid market is segmented int o the US, Canada, and Mexico. The US dominated the North America organoid market in 2022.
STEMCELL Technologies Inc, Cellesce Ltd, Organoid Therapeutics, 3Dnamics Inc, Thermo Fisher Scientific Inc, Merck KGaA, and InSphero are some of the leading companies operating in the North America organoids market.
Growing Adoption of Personalized Drugs Fuel North America Organoids Market
Personalized medicine, also known as precision medicine, is a medical model that practices procedures or drugs tailored to the individual patient based on the projected response or risk of disease. According to a study published by Personalized Medicine Coalition (PMC), personalized medicines accounted for only 5% of the new FDA-approved molecular entities in 2005, whereas they accounted for more than 25% in 2016. Additionally, 42% of all compounds and 73% of oncology compounds in the pipeline have the potential to be personalized medicines. Moreover, biopharmaceutical companies nearly doubled their R&D investment in personalized drugs over the past five years, which is likely to increase by 33% in the next five years. Biopharmaceutical researchers also predict a 69% increase in the development of personalized medicines over the coming five years. According to the latest report by the PMC (published in 2021), in the US, the number of personalized medicines in the market has risen from 132 in 2016 to 286 in 2020. The data was shared by tracking the numbers of personalized medicine since 2008 by the PMC.
The implementation of organoids to create personalized drug therapies provides exciting opportunities for improving patient care. In addition, pharmacists play an essential role in increasing the demand for personalized medicines as they proactively educate and create awareness about precision medicine. Recent research has highlighted that more than 50% of consumers are interested in purchasing customized products or services. This demand has persuaded pharmaceutical research to develop more tailored treatments to make medicines safer and more effective.
Personalized cancer medicine is an approach to tailoring effective therapeutic strategies for each patient according to a tumor’s genomic characterization. There is an increasing demand for research in personalized tumor modeling to confirm the functional aspects of genomic drug response predictions in the preclinical setting. Numerous studies have highlighted the application of tumor organoids in personalized cancer medicine in terms of gene–drug association treatment, identification of new therapies, and prediction of patient outcomes.
Personalized cancer therapy applies specific treatments to each patient. Using personalized tumor models with similar characteristics to the original tumors may result in accurate predictions of drug responses in patients. Tumor organoid models have several advantages, such as conserving the molecular and cellular composition of the original tumor over pre-existing models. These advantages highlight the tremendous potential of tumor organoids in personalized cancer therapy, particularly in preclinical drug screening and predicting patient responses to selected treatment regimens.
North America Organoids Market Overview
The North America organoids market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest share of the North America organoids market. Rising number of patients suffering from chronic conditions and viral diseases, increasing activities in research and development, commercialization of organoid models, and breakthroughs in stem cell research are the key factors propelling the market for organoids. Also, the growing funding and grants for organoid development are favoring market expansion.
North America Organoid Market Revenue and Forecast to 2030 (US$ Million)
North America Organoids Market Segmentation
The North America organoid market is segmented into organ type, application, source, type, and country.
Based on organ type, the North America organoid market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held the largest share of the North America organoid market in 2022.
Based on application, the North America organoid market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held the largest share of the North America organoid market in 2022.
Based on source, the North America organoid market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held a larger share of the North America organoid market in 2022.
Based on type, the North America organoid market is segmented into instruments, consumables, and services. The consumables segment held the largest share of the North America organoid market in 2022.
Based on country, the North America organoid market is segmented int o the US, Canada, and Mexico. The US dominated the North America organoid market in 2022.
STEMCELL Technologies Inc, Cellesce Ltd, Organoid Therapeutics, 3Dnamics Inc, Thermo Fisher Scientific Inc, Merck KGaA, and InSphero are some of the leading companies operating in the North America organoids market.
1. INTRODUCTION
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 North America Key Insights
2.2 North America Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. NORTH AMERICA ORGANOIDS MARKET LANDSCAPE
4.1 Overview
4.2 North America PEST Analysis
5. NORTH AMERICA ORGANOIDS MARKET - KEY INDUSTRY DYNAMICS
5.1 Key Market Drivers:
5.1.1 Increasing Demand for Tumor Modeling and Biobanking
5.1.2 Growing Adoption of Personalized Drugs
5.1.3 Rising Focus on Developing Alternatives for Animal Testing Models
5.2 Key Market Restraints:
5.2.1 Issues Related to Incorporation of Organoids into Existing Workflows
5.2.2 Dearth of Skilled Professionals
5.3 Key Market Opportunities:
5.3.1 Focus on Drug Discovery Activities
5.4 Future Trends:
5.4.1 Combining Organoid with Organ-On-A-Chip
5.5 Impact Analysis:
6. ORGANOIDS MARKET – NORTH AMERICA MARKET ANALYSIS
6.1 North America Organoids Market Revenue (US$ Mn), 2022 – 2030
7. NORTH AMERICA ORGANOIDS MARKET – REVENUE AND FORECAST TO 2030 – BY ORGAN TYPE
7.1 Overview
7.2 North America Organoids Market Revenue Share, by Organ Type 2022 & 2030 (%)
7.3 Stomach
7.3.1 Overview
7.3.2 Stomach: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Intestine
7.4.1 Overview
7.4.2 Intestine: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.4.3
7.5 Liver
7.5.1 Overview
7.5.2 Liver: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Pancreas
7.6.1 Overview
7.6.2 Pancreas: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Lung
7.7.1 Overview
7.7.2 Lung: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.8 Brain
7.8.1 Overview
7.8.2 Brain: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.9 Kidney
7.9.1 Overview
7.9.2 Kidney: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.10 Others
7.10.1 Overview
7.10.2 Others: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8. NORTH AMERICA ORGANOIDS MARKET – REVENUE AND FORECAST TO 2030 – BY APPLICATION
8.1 Overview
8.2 North America Organoids Market Revenue Share, by Application 2022 & 2030 (%)
8.3 Developmental Biology
8.3.1 Overview
8.3.2 Developmental Biology: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Disease Pathology of Infectious Disease
8.4.1 Overview
8.4.2 Disease Pathology of Infectious Disease: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Regenerative Medicine
8.5.1 Overview
8.5.2 Regenerative Medicine: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Drug Toxicity and Efficacy Testing
8.6.1 Overview
8.6.2 Drug Toxicity and Efficacy Testing: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.7 Drug Discovery and Personalized Medicine
8.7.1 Overview
8.7.2 Drug Discovery and Personalized Medicine: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
9. NORTH AMERICA ORGANOIDS MARKET – REVENUE AND FORECAST TO 2030 – BY SOURCE
9.1 Overview
9.2 North America Organoids Market Revenue Share, by Source 2022 & 2030 (%)
9.3 Pluripotent Stem Cells
9.3.1 Overview
9.3.2 Pluripotent Stem Cells: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Organ-specific Adult Stem Cells
9.4.1 Overview
9.4.2 Organ-specific Adult Stem Cells: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
10. NORTH AMERICA ORGANOIDS MARKET – REVENUE AND FORECAST TO 2030 – BY TYPE
10.1 Overview
10.2 North America Organoids Market Revenue Share, by Type 2022 & 2030 (%)
10.3 Instruments
10.3.1 Overview
10.3.2 Instruments: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
10.4 Consumables
10.4.1 Overview
10.4.2 Consumables: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
10.5 Services
10.5.1 Overview
10.5.2 Services: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
11. NORTH AMERICA ORGANOIDS MARKET - COUNTRY ANALYSIS
11.1 North America: Overview
11.1.1 North America Organoids Market, by Country
11.1.1.1 US
11.1.1.1.1 Overview
11.1.1.1.2 US Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.1.3 US Organoids Market, by Organ Type
11.1.1.1.4 US Organoids Market, by Application
11.1.1.1.5 US Organoids Market, by Source
11.1.1.1.6 US Organoids Market, by Type
11.1.1.2 Canada
11.1.1.2.1 Overview
11.1.1.2.2 Canada Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.2.3 Canada Organoids Market, by Organ Type
11.1.1.2.4 Canada Organoids Market, by Application
11.1.1.2.5 Canada Organoids Market, by Source
11.1.1.2.6 Canada Organoids Market, by Type
11.1.1.3 Mexico
11.1.1.3.1 Overview
11.1.1.3.2 Mexico Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.3.3 Mexico Organoids Market, by Organ Type
11.1.1.3.4 Mexico Organoids Market, by Application
11.1.1.3.5 Mexico Organoids Market, by Source
11.1.1.3.6 Mexico Organoids Market, by Type
12. PRE & POST COVID-19 IMPACT
12.1 Pre & Post Covid-19 Impact
13. NORTH AMERICA ORGANOIDS MARKET INDUSTRY LANDSCAPE
13.1 Overview
13.2 Growth Strategies Done by the Companies in the Market, (%)
13.3 Organic Developments
13.3.1 Overview
13.4 Inorganic Developments
13.4.1 Overview
14. NORTH AMERICA ORGANOIDS MARKET, KEY COMPANY PROFILES
14.1 STEMCELL Technologies Inc.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Cellesce Ltd
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Organoid Therapeutics
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4.3Dnamics Inc.
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Thermo Fisher Scientific Inc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Merck KGaA
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 InSphero
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
15. APPENDIX
15.1 About Us
15.2 Glossary of Terms
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 North America Key Insights
2.2 North America Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. NORTH AMERICA ORGANOIDS MARKET LANDSCAPE
4.1 Overview
4.2 North America PEST Analysis
5. NORTH AMERICA ORGANOIDS MARKET - KEY INDUSTRY DYNAMICS
5.1 Key Market Drivers:
5.1.1 Increasing Demand for Tumor Modeling and Biobanking
5.1.2 Growing Adoption of Personalized Drugs
5.1.3 Rising Focus on Developing Alternatives for Animal Testing Models
5.2 Key Market Restraints:
5.2.1 Issues Related to Incorporation of Organoids into Existing Workflows
5.2.2 Dearth of Skilled Professionals
5.3 Key Market Opportunities:
5.3.1 Focus on Drug Discovery Activities
5.4 Future Trends:
5.4.1 Combining Organoid with Organ-On-A-Chip
5.5 Impact Analysis:
6. ORGANOIDS MARKET – NORTH AMERICA MARKET ANALYSIS
6.1 North America Organoids Market Revenue (US$ Mn), 2022 – 2030
7. NORTH AMERICA ORGANOIDS MARKET – REVENUE AND FORECAST TO 2030 – BY ORGAN TYPE
7.1 Overview
7.2 North America Organoids Market Revenue Share, by Organ Type 2022 & 2030 (%)
7.3 Stomach
7.3.1 Overview
7.3.2 Stomach: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Intestine
7.4.1 Overview
7.4.2 Intestine: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.4.3
7.5 Liver
7.5.1 Overview
7.5.2 Liver: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Pancreas
7.6.1 Overview
7.6.2 Pancreas: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Lung
7.7.1 Overview
7.7.2 Lung: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.8 Brain
7.8.1 Overview
7.8.2 Brain: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.9 Kidney
7.9.1 Overview
7.9.2 Kidney: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.10 Others
7.10.1 Overview
7.10.2 Others: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8. NORTH AMERICA ORGANOIDS MARKET – REVENUE AND FORECAST TO 2030 – BY APPLICATION
8.1 Overview
8.2 North America Organoids Market Revenue Share, by Application 2022 & 2030 (%)
8.3 Developmental Biology
8.3.1 Overview
8.3.2 Developmental Biology: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Disease Pathology of Infectious Disease
8.4.1 Overview
8.4.2 Disease Pathology of Infectious Disease: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Regenerative Medicine
8.5.1 Overview
8.5.2 Regenerative Medicine: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Drug Toxicity and Efficacy Testing
8.6.1 Overview
8.6.2 Drug Toxicity and Efficacy Testing: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.7 Drug Discovery and Personalized Medicine
8.7.1 Overview
8.7.2 Drug Discovery and Personalized Medicine: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
9. NORTH AMERICA ORGANOIDS MARKET – REVENUE AND FORECAST TO 2030 – BY SOURCE
9.1 Overview
9.2 North America Organoids Market Revenue Share, by Source 2022 & 2030 (%)
9.3 Pluripotent Stem Cells
9.3.1 Overview
9.3.2 Pluripotent Stem Cells: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Organ-specific Adult Stem Cells
9.4.1 Overview
9.4.2 Organ-specific Adult Stem Cells: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
10. NORTH AMERICA ORGANOIDS MARKET – REVENUE AND FORECAST TO 2030 – BY TYPE
10.1 Overview
10.2 North America Organoids Market Revenue Share, by Type 2022 & 2030 (%)
10.3 Instruments
10.3.1 Overview
10.3.2 Instruments: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
10.4 Consumables
10.4.1 Overview
10.4.2 Consumables: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
10.5 Services
10.5.1 Overview
10.5.2 Services: North America Organoids Market – Revenue and Forecast to 2030 (US$ Million)
11. NORTH AMERICA ORGANOIDS MARKET - COUNTRY ANALYSIS
11.1 North America: Overview
11.1.1 North America Organoids Market, by Country
11.1.1.1 US
11.1.1.1.1 Overview
11.1.1.1.2 US Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.1.3 US Organoids Market, by Organ Type
11.1.1.1.4 US Organoids Market, by Application
11.1.1.1.5 US Organoids Market, by Source
11.1.1.1.6 US Organoids Market, by Type
11.1.1.2 Canada
11.1.1.2.1 Overview
11.1.1.2.2 Canada Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.2.3 Canada Organoids Market, by Organ Type
11.1.1.2.4 Canada Organoids Market, by Application
11.1.1.2.5 Canada Organoids Market, by Source
11.1.1.2.6 Canada Organoids Market, by Type
11.1.1.3 Mexico
11.1.1.3.1 Overview
11.1.1.3.2 Mexico Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.3.3 Mexico Organoids Market, by Organ Type
11.1.1.3.4 Mexico Organoids Market, by Application
11.1.1.3.5 Mexico Organoids Market, by Source
11.1.1.3.6 Mexico Organoids Market, by Type
12. PRE & POST COVID-19 IMPACT
12.1 Pre & Post Covid-19 Impact
13. NORTH AMERICA ORGANOIDS MARKET INDUSTRY LANDSCAPE
13.1 Overview
13.2 Growth Strategies Done by the Companies in the Market, (%)
13.3 Organic Developments
13.3.1 Overview
13.4 Inorganic Developments
13.4.1 Overview
14. NORTH AMERICA ORGANOIDS MARKET, KEY COMPANY PROFILES
14.1 STEMCELL Technologies Inc.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Cellesce Ltd
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Organoid Therapeutics
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4.3Dnamics Inc.
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Thermo Fisher Scientific Inc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Merck KGaA
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 InSphero
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
15. APPENDIX
15.1 About Us
15.2 Glossary of Terms
